Share

March 2018; 5 (2) ArticleOpen Access

Cervical spinal cord atrophy

An early marker of progressive MS onset

Burcu Zeydan, Xinyi Gu, Elizabeth J. Atkinson, B. Mark Keegan, Brian G. Weinshenker, Jan-Mendelt Tillema, Daniel Pelletier, Christina J. Azevedo, Christine Lebrun-Frenay, Aksel Siva, Darin T. Okuda, Kejal Kantarci, Orhun H. Kantarci
First published January 22, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000435
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
744

Share

Article Information

vol. 5 no. 2 e435
DOI: 
https://doi.org/10.1212/NXI.0000000000000435
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received May 24, 2017
  • Accepted in final form November 28, 2017
  • First Published January 22, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Burcu Zeydan, MD,
    2. Xinyi Gu, MD,
    3. Elizabeth J. Atkinson, MS,
    4. B. Mark Keegan, MD,
    5. Brian G. Weinshenker, MD,
    6. Jan-Mendelt Tillema, MD,
    7. Daniel Pelletier, MD,
    8. Christina J. Azevedo, MD,
    9. Christine Lebrun-Frenay, MD,
    10. Aksel Siva, MD,
    11. Darin T. Okuda, MD,
    12. Kejal Kantarci, MD, MS and
    13. Orhun H. Kantarci, MD
  1. Burcu Zeydan, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Turkish Neurological Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Xinyi Gu, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Elizabeth J. Atkinson, MS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec Industry -- Lab-based, Re-analyses of champs and champions data, co-investigator, 1/31/2017 - 1/30/2018

    Research Support, Government Entities:

    1. NIA P01AG 04875-33, Co-investigator, 6/15/2015-4/30/2020 Physiology of Bone Metabolism in an Aging Population

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. B. Mark Keegan, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)Multiple Sclerosis and Related Disorders 2011-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Bristol Meyers Squibb, Bionest

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen: ARISE study

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Brian G. Weinshenker, MD,
    6. Scientific Advisory Boards:

    1. (1) Novartis data safety monitoring board member (2) Mitsubishi Pharmaceuticals data safety monitoring board member

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation 3. Neurology, editorial board member, 2014-present; no compensation

    Patents:

    1. 1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.,Oxford University,MVZ Labor PD Dr. Volkmann und Kollegen GbR, Hospices Civil de Lyon

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Caladrius: consulting regarding design of neuromyelitis optica clinical trial 2. Brainstorm Therapeutics: consulting regarding design of neuromyelitis optica clinical trial

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1)MedImmune Pharmaceuticals, Adjudication Committee Member (2)Alexion Pharmaceuticals, Adjudication Committee Member

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-08/2017

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR and Hospices Civil de Lyon

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jan-Mendelt Tillema, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NCATS/NIH. KL2TR000136-09

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Daniel Pelletier, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pelletier received consulting fees from Biogen, EMD Serono, Sanofi-Genzyme, Novartis, Hoffmann LaRoche, and Actelion.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Christina J. Azevedo, MD,
    9. Scientific Advisory Boards:

    1. Advisory boards for Genzyme, Guerbet, Genentech, and Biogen-Idec

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Institutional Career Development Award through the University of Southern California Clinical and Translational Science Institute, Grant # UL1TR001855

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Race to Erase MS Foundation Young Investigator Award

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Christine Lebrun-Frenay, MD,
    10. Scientific Advisory Boards:

    1. serving on a scientific advisory board from Biogen, Novartis, Merck, Genzyme,Teva, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for travel or speaker honoraria from Biogen, Merck, Genzyme, Roche

    Editorial Boards:

    1. Serving as editorial advisory board member for Revue Neurologique (Paris) Elsevier, Neurology and therapy.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. UT Southwestern, Dallas, TX. Clinical advisor and senior professor.

    Research Support, Foundations and Societies:

    1. Franch MS Society (SFSEP) EDMUS (OFSEP Center) Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Aksel Siva, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Siva received travel and registration coverage for attending several national or international congresses or symposia, from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Novartis, Sanofi-Genzyme, Roche and Teva (all unrelated to this work).

    Editorial Boards:

    1. Journal of Neurological Sciences (editorial board member / no compensation) Journal of Headache and Pain (editorial board member / no compensation) Turkish Neurological Journal (editorial board member / no compensation)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr Siva reports receiving honoraria or consultation fees from the commercial entities of Biogen Idec, Novartis, Merck-Serono, Bayer, Teva, Sanofi-Genzyme and Roche within the last two years (all unrelated to this work).

    Speakers' Bureaus:

    1. Giving educational presentations at programmes & symposia prepared by Excemed internationally - nonprofit entity (all unrelated to this work) and honoraria for giving educational presentations at several national or international congresses or symposia and consultation fees from Sanofi- Genzyme, Merck Serono, Biogen Idec / Gen Pharma of Turkey and Teva

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Siva reports receiving research grants to his department from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants numbers : 109S070 and 112S052 - noncommercial entity. / unrelated to the study submitted

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Darin T. Okuda, MD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1). Acorda Therapeutics, travel and speaker fees (2). Genentech, travel and speaker fees (3). Genzyme, travel and speaker fees (4). Teva, travel and speaker fees

    Editorial Boards:

    1. NONE

    Patents:

    1. 1. Methods, Apparatuses, and Systems for Creating 3- Dimensional Representations Exhibiting Geometric and Surface Characteristics of Brain Lesions UTSD.P3102US.P1/11606483 (Pending) 2. System and method for medical surveillance through personal communication device US15/356,342 (Pending)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1). Celgene (2). Bayer (3). EMD Serono (4). Genzyme (5). Novartis

    Speakers' Bureaus:

    1. (1). Acorda Therapeutics (2). Genzyme (3). TEVA Neuroscience

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Kejal Kantarci, MD, MS and
    13. Scientific Advisory Boards:

    1. Data safety monitoring board member for Takeda Global Research & Development Center, Inc., Pfizer Inc. and Janssen Alzheimer Immunotherapy

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. R01 AG040042 (PI); 2011-2018, P50AG044170/P2(PI); 2012- 2017;U01 NS100620 (PI); RF1 AG057547 (PI)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Minnesota Partnership for Biotechnology and Medical Genomics; 2013-2015

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Orhun H. Kantarci, MD
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Istanbul MS Days, Novartis Pharmaceuticals, speaker honoraria payment to Mayo Clinic. No personal compensation. 2) Invited professor program, Biogen- Boston, speaker honoraria payment to Mayo Clinic. No personal compensation

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Grant review for The National Multiple Sclerosis Society.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Already listed in the paper but reported again: Dr. Orhun Kantarci receives research support from Biogen. Dr.Kejal Kantarci serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Government Entities:

    1. Dr.Kejal Kantarci (wife) serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Academic Entities:

    1. Dr.Kejal Kantarci (wife) serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])

    Research Support, Foundations and Societies:

    1. 2006-2009 Multiple Sclerosis Society for support in multiple sclerosis research unrelated to this publication; 2008-2009 Mayo Foundation CR20 award for support in multiple sclerosis research unrelated to this publication; 2009-2011 Hilton Foundation support in multiple sclerosis research unrelated to this publication

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (B.Z., X.G., B.M.K., B.G.W., J.-M.T., O.H.K.), Department of Radiology (B.Z., K.K.), and Department of Health Sciences Research (E.J.A.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology (X.G.), The affiliated ZhongShan Hospital of DaLian University, LiaoNing, China; Multiple Sclerosis Center (D.P., C.J.A.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Neurology (C.L.-F.), Hopital Pasteur, Nice, France; Cerrahpasa School of Medicine (A.S.), Istanbul University, Turkey; and Department of Neurology & Neurotherapeutics (D.T.O.), Clinical Center for Multiple Sclerosis, University of Texas Southwestern Medical Center, Dallas.
  1. Correspondence to
    Dr. Kantarci kantarci.orhun{at}mayo.edu
View Full Text

Article usage

Article usage: January 2018 to June 2019

AbstractFullPdfSource
Jan 2018019624Highwire
Feb 2018094383Highwire
Mar 20181929115Highwire
Apr 20180115929Highwire
Apr 201862122pmc
May 2018054418Highwire
Jun 2018028415Highwire
Jun 201893544pmc
Jul 2018034585Highwire
Aug 2018126217Highwire
Aug 201873538pmc
Sep 2018027830Highwire
Oct 2018037127Highwire
Nov 2018035928Highwire
Dec 2018044119Highwire
Jan 2019348511Highwire
Feb 20191541225Highwire
Mar 2019729838Highwire
Apr 2019723836Highwire
May 2019821825Highwire
Jun 2019624315Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement